Pharmacy Podcast Network

TWIRx | Cost+ Specialty Pharmacy

Lumicera is unique in that it was one of the first to provide transparency to the market. It became the first national, Cost+ Specialty Pharmacy providing clients with true acquisition plus a flat patient management fee pricing model utilizing First-In-First-Out (FIFO) inventory pricing model. Lumicera serves Navitus members, a PBM that employs a full pass-through model, where they pass 100% of all network discounts and pharmaceutical manufacturer rebates they receive directly back to the client, and just celebrated their millionth shipment of specialty medications.

Guest Interview: Austin Rogers and Cheri Thomas of Northwest Ketamine Clinic | Neural Pharm Podcast

Colby sits down with NW Ketamine Clinic Operations Manager Austin Rogers and Clinical Director Cheri Thomas to provide an overview of the Ketamine Assisted Psychotherapy patient experience
*For listeners in the Seattle/Tacoma/Bellevue area: Mention this podcast and receive 10% off an initial ketamine treatment series at NW Ketamine Clinic
For more information go to: https://nwketamineclinics.com/

CBD Use in the Pediatric Population | Pediatric Pharmacist Review

https://meridian.allenpress.com/jppt/article-abstract/28/4/323/494868/Parental-Perceptions-and-Usage-of-Unlicensed?redirectedFrom=fulltextHost-Jena Quinn, PharmD, BCPPSGuest Name- Justin Cole, PharmD, BCPSJustin Cole, PharmD, BCPS, has nearly 2 decades of experience in pediatric pharmacy practice and healthcare innovation. Dr. Cole earned his PharmD from Ohio Northern University.  He began his career at Nationwide Children’s Hospital in Columbus, Ohio, where he developed expertise in general pediatrics, pediatric neurology, and medical education. While at Nationwide Children's he also served on the administrative team, providing leadership of clinical pharmacy services, oversight of investigational drug services, and strategic vision for novel clinical pharmacy solutions to meet the unique needs of children.Dr. Cole now serves as Chair and Associate Professor of Pharmacy Practice at the Cedarville University School of Pharmacy. He is also the founding director of the Cedarville University Center for Pharmacy Innovation. He has been recognized by Cedarville University as Preceptor of Distinction in 2016, Distinguished Pharmacy Faculty Member in 2022, and Faculty Innovator of the Year in 2023. He was also awarded the inaugural award for Excellence in Teaching in Pediatric Pharmacy from the American Association of Colleges of Pharmacy in 2021. Dr. Cole is an active member of the Pediatric Pharmacy Association and the American Society of Health-System Pharmacists. He has authored or co-authored numerous papers and publications, including Ethics in Pharmacy Practice: A Practical Guide. His research and teaching interests include pediatric pharmacy practice, evidence-based communication strategies in pediatrics, practice advancement and innovation, and healthcare ethics. He continues to practice as a pediatric clinical pharmacist at Rocking Horse Community Health Center in Springfield, Ohio.Dr. Cole and his wife Michelle have three wonderful kids. He and his family enjoy hiking, backpacking, backyard gardening, serving in his church, and enjoying sports together.

Become a Pharmacist Entrepreneur: The Decision to Transition | Pharmacist Diaries

From the busy corridors of the hospital to the whirlwind of entrepreneurship, this episode takes you through a remarkable journey. It’s a honest conversation between Yasir Sacranie, the CEO of MicroPharm, and yours truly, where we unveil our exhilarating transition from the world of specialised hospital pharmacy to starting our own businesses. We lay bare the hurdles we have encountered and the driving force that kept us going. You'll hear us delve into the inception of Pharmacist Diaries and MicroPharm, and the early challenges we tackled in setting up these ventures.
 
Striking a balance between your professional and personal life is crucial, especially in the realm of entrepreneurship - this is a subject we address head-on in our chat. We explore the importance of managing time, both work and sleep, for overall well-being. If you've got a burning idea or a passion, listen up! 
We offer you our insights and experiences and encourage you to make the jump, but stress the importance of doing your homework. We talk about the necessary mindset and skills to construct your dream project from scratch. 
And remember - entrepreneurship is a journey - it's completely okay to step out of your comfort zone and experiment. Stay tuned for the next episode where we delve deeper into the essential skillset of an entrepreneur.
PARTNERSHIPS:
The Naked Pharmacy is offering my podcast listeners a 20% discount on all their products. Use discount code PD20 at checkout to receive the offer.
 
SUPPORT THE PODCAST:
As I continue to grow and evolve this podcast, I am committed to bringing you inspiring and empowering content. But in order to do that, I need your support. I've set up a Buy Me a Coffee donation page where you have the opportunity to donate a coffee (£5). You'll be helping us invest in the infrastructure, equipment, and team needed to take Pharmacist Diaries to the next level. With your help, we can continue to inspire and empower pharmacists around the world, and create a community that supports and uplifts one another.
 
CONNECT WITH YASIR:
LinkedIn: Yasir Sacranie
Instagram: @micrpharm
YouTube: @micrpharm
Twitter: @micropharmorg
tikTok: @micropharm
MicroPharm Website
FILMED AND EDITED BY:
Sunjay Vyas
 
Follow me on My Website, YouTube, Instagram, Facebook, LinkedIn, and/or Twitter. Feel free to subscribe to the podcast on your favourite podcast platform so you can be notified when a new episode is released or leave a review on apple podcasts. If you have any suggestions for guests you want me to talk to or if you’d like to come on yourself, please feel free to contact me via social media, or email at info@pharmacistdiaries.com.
 
🌟 Exciting News for the Paediatric and Neonatal Pharmacy Community! 🌟Did you know about the upcoming Neonatal and Paediatric Pharmacy Conference, scheduled to take place from November 3rd to 5th, 2023 in Cheshire? This event promises to be a game-changer for all professionals dedicated to the well-being of our littlest patients.👶 Why should you attend this conference?1️⃣ Cutting-Edge Insights: Stay at the forefront of the latest advancements in neonatal and paediatric pharmacy with steve tomlin2️⃣ Networking Opportunities: Connect with peers, mentors, and professionals who share your passion for improving the healthcare outcomes of neonates and children.3️⃣ Interactive Workshops and Panel Discussions: Dive deep into hands-on workshops designed to enhance your clinical skill in epilepsy, palliative care, asthma, prescribing, cancer, childhood infections, drugs and feeding tubes and more. Gain practical knowledge that you can immediately apply in your daily practice.4️⃣ Inspirational Speakers: Be inspired by keynote speakers who have made remarkable contributions to paediatric and neonatal healthcare. Their stories and insights will motivate and empower you. Emma Kirk Alison Tennant5️⃣ Research and Innovation: Explore groundbreaking research and innovative solutions that are shaping the future of paediatric and neonatal care. Discover new ways to improve patient outcomes.6️⃣ Masterclass sessions: Learn more about Type I Diabetes, Genomic Medicine and Management of Skin Conditions Nicola Husain7️⃣ Motivational Speaker: How to beat pharmacy burnout - solution through prevention Harpreet Chana MRPharmS, CPC, ELI-MP✨ Let's make a difference together! Join us at the Neonatal and Paediatric Pharmacy Conference and be a part of the transformative journey in healthcare.Registration is now open! Don't miss out on this incredible opportunity to expand your knowledge, network with like-minded professionals, and contribute to the well-being of our tiniest patients.📅 Save the Date:🗓️ November 3-5, 2023📍 Cranage Hall, CheshireLet's come together to advance the care of neonates and children, ensuring a brighter and healthier future for them. See you at the conference!#PaediatricPharmacy #NeonatalCare #HealthcareConference #ProfessionalDevelopment #PediatricHealth #ChildHealthcare #MedicalInnovation #NetworkingEvent

The Volunteer State takes a Stand on PBMs | PBM Reform

Featuring Tennessee State Senator & Pharmacist Shane Reeves"The Volunteer State" has been a Tennessee nickname since the 19th century but wasn't officially voted on until February 2020. Tennessee sent 1,500 volunteer soldiers during the War of 1812, and the nickname stuck.Requiring PBMs to contract with rural independent pharmacies: In Tennessee, there are 70 counties considered rural out of the 95 counties in the state. Tennessee lost 15 rural hospitals over the last few years, so healthcare access is an issue. Most of these towns have a community pharmacy which is the access point for a lot of health care and health care information for many Tennesseans. About Shane Reeves: Man of Faith, Husband, Father, CEO, Pharmacist, Public Servant (TN State Senator)As CEO of TwelveStone Health Partners, Shane's mission is to be the regional leader in post-acute chronic care pharmacy management, placing patients and their families at the center of everything he does. As faithful stewards, Shane leads his team to strive every day to glorify God. 

One Pharmacist’s Journey From Band-Aid Medicine to Whole Body Health w/ Dr. Lara May, PharmD | The Holistic Pharmacy Podcast

Hi dear listeners! I am so excited to introduce my next guest, a like-minded soul who believes that chronic diseases don't have to be chronic. They are reversible and preventable with the right lifestyle choices. Healing is not one size fits all, which is why today’s guest practices functional medicine and energy healing. We talk about getting to the root cause of inflammation, which is the key to disease reversal and it is accessible to all. Dr. Lara May is a Functional Medicine Clinical Specialist, Master Energy Healer & Channel & International Speaker who specializes in getting to the root cause of disease via functional medicine. She has worked in emergency rooms and adult acute care for a decade, counseling nurses, doctors, patients & families about medication regimens and maximizing treatment outcomes. Due to her struggle with her own health, Lara started studying & practicing functional medicine in 2017. Lara’s passion & mission is to empower patients to take an active role in their health, so that they can create their health on their terms. It was during the COVID pandemic that Lara decided to focus on helping type 2 diabetics understand and reverse their disease, after she witnessed the increased death rates as a consequence of diabetes as a comorbidity. Type 2 diabetes is completely preventable and reversible, yet its numbers are growing every year. Dr Lara believes that if patients are given the tools and knowledge they will make the right decisions for their health. This is her mission.Connect with Dr. Lara May via:drlaramay.com/  @drlaramay on all socials Light Body Radio Podcast - https://www.drlaramay.com/podcast Dr. Lara May shares her guide to kicking sugar addiction here: https://www.drlaramay.com/kickthesugarMarina Buksov, PharmD; Dr. Lara May, PharmD

Exploring GLP-1 Agonists: Sports Pharmacology and Beyond with Dr. Jesica Mills | Sports Pharmacy Podcast

In this episode of "glp1 with Jesica Mills", Dr. H and Dr. Jesica Mills plunge into an in-depth exploration of GLP-1 (Glucagon-like peptide-1) agonists and their intriguing role in sports pharmacology. Learn about the complexities of these medications, their contribution to diabetes management, and their influence on weight loss. Learn how GLP-1 agonists are becoming a topic of interest due to their interaction with the beta cells of the pancreas, regulating blood sugar levels, and how diet and lifestyle tangibly affect the production of GLP-1 in the body.Listen to our discussions surrounding the potential side effects, the need for careful monitoring, the off-label uses of these medications, and their potential implications. Further delve into the alternatives to GLP-1 agonists like acarbose and natural approaches to boost GLP-1 levels employing over-the-counter supplements like berberine and lifestyle adjustments. The conversation extends to understanding the lymphatic system, the importance of routine checkups, lab tests, and the role of micronutrients. Join us on this captivating itinerary exploring the beneficial yet challenging world of GLP-1 agonists!

Leveraging Long Term Care at Home Network | Happier at Home PRN

Long-Term Care at Home Pharmacy Network 
Lindsay Dymowski ConstantinoPresident, Co-founder 
Lindsay is a dynamic pharmacy leader who drives strategic initiatives, fosters industry-wide collaboration, and advocates passionately for optimal patient care. With a deep-rooted connection to community pharmacy, extensive ownership experience spanning more than 10 years and her pioneering role in the long-term care at home market, Lindsay has been a driving force in advancing healthcare innovation and elevating the role of community pharmacy in shaping the future of patient-centered care.
New boost

The Extra Dose: User Conference Post-Show Part Two | Framework Focus

This is part two of the three-part FrameworkLTC User Conference Post-Show series. This series is hosted by the Pharmacy Podcast Network’s own Todd Eury. In this series, Todd chats with SoftWriters’ team members, exhibitors, partners, and conference attendees live from the show floor. This episode features Joshua Porter, Grace Ball, Julie Martin, Matt Gilbert, and Nick Majors. 

Understanding Insufficient GLP-1 Activity in T2D | T2D: Don’t Sugar Coat It

What is the impact of insufficient GLP-1 activity in type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson, Dr Javier Morales, and Dr Richard Pratley as they review the role of GLP-1 in glucose regulation, consider the impact of insufficient GLP-1 activity on pancreatic beta cells in patients with T2D, and discuss possibilities to overcome insufficient GLP-1 activity in patients with T2D.
 
John E. Anderson, MD
Javier Morales, MD, FACP, FACE
Richard Pratley, MD
 

When you just can’t figure out your ”Why” | PharmXcel

How can you figure out your Why?Can you live for more than one Cause?Is your Pharmacy career externally or internally driven?The importance of spending time to figure out your WhyReferences:Book - Simon Sinek: The Infinite GameBook - Sonja Lyubomirsky: The How of Happiness: A New Approach to Getting the Life You WantVisit www.katrinaazer.com to find out how I can help you to:👉 Figure out what your purpose is and how you can weave that into your career👉 Get coached into figuring out and building your dream career👉 Find out how to build a side hustle that earns you income👉 Bring Pharmacogenomics & Telepharmacy to your practiceFollow me on social media:➡️ LinkedIn: https://www.linkedin.com/in/katrina-azer/➡️ Facebook: https://www.facebook.com/pharmxcel➡️Twitter: https://twitter.com/Kat_pharmacistThe PharmXcel Podcast is a show for pharmacists who want to connect with why they did pharmacy and how to build a fulfilling career by addressing the opportunities and challenges that make us pharmacists—Pharmacists who signed up for pharmacy to help transform patient lives!Thanks for listening in—it means the world to me!Here is how you can support my mission:Give it a 5-star rating wherever you’re listening to itShare this with other Pharmacists who would enjoy itSubscribe to get notified of new episodesAnd please reach out if you have any questions or comments!Your feedback will help me bring you valuable content

From ACPHS to Precision Genomics Oncology | Occupation Station

In this episode of Occupation Station, host Diane Donato speaks with Christopher Fausel '96, Director of Pharmacy, Precision Genomics Oncology at Indiana University Simon Comprehensive Cancer Center. The ACPHS graduate delves into the fascinating world of precision medicine, where tumor DNA is analyzed to create personalized treatment plans. While the field presents challenges due to its rapid evolution, Fausel finds his work helping cancer patients extremely gratifying and sees a future of unlimited possibilities. He talks about his decision to become a pharmacist, his studies at ACPHS, and how his work at Stratton V.A. in Albany were all precursors to his current position. Fausel encourages pharmacy students to explore diverse opportunities during their residencies and embrace emerging technologies. Fausel's story is an inspiring reminder that pharmacy careers offer endless possibilities for making a meaningful impact on patients' lives.
  
I attach the 1080x1080 social media tile and some audiograms that could be used to tease the episode on your social media platforms. Here is some copy for the audiograms:
 
Fausel 1
Join us for an insightful conversation with Christopher Fausel ’93 ‘96, Director of Pharmacy at Indiana University Simon Comprehensive Cancer Center. Discover the remarkable rewards of working with cancer patients, as well as Christopher's inspiring career journey. Find out how tumor DNA analysis is transforming personalized treatment plans. https://tinyurl.com/5cb82yzf
 
Fausel 2
Get ready to dive into the fascinating world of precision medicine with Christopher Fausel '93 '96, Director of Pharmacy at Indiana University Simon Comprehensive Cancer Center. Discover how tumor DNA analysis is revolutionizing personalized treatment plans. And be inspired by Fausel's advice to pharmacy students to keep an open mind to all the incredible opportunities that await! https://tinyurl.com/5cb82yzf

TWIRx | Leading Pediatric Pharmacist & The Best of the Best Celebration Episode

We're celebrating with special guests for SingleCare's 2023 Best of the Best award winning pharmacist Dr. Jan Marie Salcido, Pharm.D along with Dr. Jen Bourgeois, PharmD. 

NASP 2023 Annual Meeting LIVE ReCap Show Part Three | NASP Specialty Pharmacy Podcast

Episode 3 of the NASP Post Show! In this episode we talk with
Nicholas Ruiz - keycentrix
Richard Brook - Better Health Worldwide / NPRT
Russel Robbins - PurpleLab
Saumya Rawat - Pharmesol
David Bronstein - Specialty Pharmacy Continuum
Tim McLeroy - Noble International

From PharmD to Pharmacogenomics Test Developer: Dr. Thierry Dervieux’s Story of Revolutionizing Healthcare Through Precision Medicine for Immune Modulated Inflammatory Diseases | PGx For Pharmacists

Becky Winslow, BS, PharmD Host and Pharmacogenomics Medical Science Liaison; Behnaz Sarrami, MS, PharmD, Host and Pharmacogenomics Medical Science Liaison; Thierry Dervieux, PharmD, PhD, Chief Scientific Officer at Prometheus Laboratories
In this episode of the PGX for Pharmacists Podcast, Dr. Thierry Dervieux, Dr. Behnaz Sarrami, and I discuss Dr. Dervieux’s career as a PharmD,PhD, and chief scientific officer who has designed a pharmacogenomics test prescribers may use to optimize biosimilars for autoimmune gastrointestinal diseases. Dr. Dervieux will illustrate to our audience pharmacogenomics’ potential beyond Tier 1 and 2 genetic testing by describing the clinical validity and utility of his laboratory’s suite of tests in the autoimmune gastrointestinal disease diagnosis and treatment market. Behnaz and I hope this episode will inspire pharmacists interested in pharmacogenomics to think beyond the boxed PGx test most laboratories offer when they think about PGx and consider all the biological systems in which genetics impacts drugs’ efficacy and safety.
Disclaimer:Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc. Becky Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of any other entity.
 
Transcription:
100:00:06,190 --> 00:00:19,620You're listening to the Pharmacy podcast Network in a world where one size fits all medications dominate the pharmaceutical industry.
200:00:20,079 --> 00:00:24,750Precision medicine brings a ray of hope for those seeking customized health care.
300:00:25,350 --> 00:00:32,830Pharmacists have a unique opportunity to help people in need of specialized testing to ensure medications work as intended.
400:00:33,540 --> 00:00:44,680Welcome to PGX for pharmacists where we unravel the wonders of precision medicine and its potential to revolutionize the way we approach pharmacy care.
500:00:45,169 --> 00:00:52,790Get ready to uncover the secrets behind pharmacogenomics and how it's transforming lives one genome at a time.
600:00:52,799 --> 00:00:53,189Hello,
700:00:53,200 --> 00:00:53,950everyone.
800:00:54,159 --> 00:00:55,080I'm your host,
900:00:55,090 --> 00:00:56,389Doctor Becky Winslow.
1000:00:56,409 --> 00:01:09,860And you're listening to the PGX for Pharmacist podcast that we magazine recognized in 2021 as the ninth most listened to genetics podcasts in the world on the PGX for Pharmacist podcast.
1100:01:09,870 --> 00:01:16,690We explore all things pharmacogenomics related and our mission is to educate and advocate for PGX.
1200:01:16,769 --> 00:01:23,849We accomplish this mission through exclusive interviews with highly qualified and well experienced pharmacogenomics.
1300:01:23,860 --> 00:01:29,720Industry leaders such as today's special guest and my name is Baas Sami,
1400:01:29,730 --> 00:01:32,739the co-host of PGX for Pharms podcast,
1500:01:32,750 --> 00:01:33,860Pharmacogenomics,
1600:01:33,870 --> 00:01:36,819medical science liaison and a mentor to pharmacist.
1700:01:36,889 --> 00:01:40,239Connect with us on linkedin and let's get a conversation going.
1800:01:40,269 --> 00:01:46,720We want to hear from you and how you're impacting pharmacogenomic stakeholders and what you have learned throughout your journey.
1900:01:48,510 --> 00:01:49,010Ok.
2000:01:49,019 --> 00:01:50,819So without any further ado,
2100:01:50,839 --> 00:01:54,769I'm extremely pleased to introduce to our audience.
2200:01:54,919 --> 00:01:56,059Doctor Theory Devo,
2300:01:57,239 --> 00:02:01,129the Chief Scientific Officer at Prometheus Laboratories,
2400:02:01,139 --> 00:02:08,139and Perme Prometheus Laboratories is a reference clinical laboratory that's focused on the diagnosis,
2500:02:08,149 --> 00:02:13,330prognosis and monitoring of immune mediated inflammatory diseases.
2600:02:13,970 --> 00:02:14,229So,
2700:02:14,240 --> 00:02:14,649thank you,
2800:02:14,660 --> 00:02:17,759Doctor De for joining us on the podcast.
2900:02:17,770 --> 00:02:18,589Today.
3000:02:18,600 --> 00:02:23,190I'm excited to share your and Prometheus's story with our audience.
3100:02:23,649 --> 00:02:25,630Um in particular,
3200:02:25,639 --> 00:02:45,369I'm excited about you sharing your career journey as a farm D phd and Chief scientific officer and designer of the Predictor PK AD A which is a precision guided dosing test for the optimization of Humira Remicade and their bio cylinders.
3300:02:46,119 --> 00:02:46,449So,
3400:02:46,460 --> 00:03:04,220one of Bana's and my main goals for this episode of the PGX for Pharmacist podcast is to expand our audience's notion of what a PGX test looks like and to inspire them to think bigger than the traditional box PGX test.
3500:03:04,229 --> 00:03:08,020Most of them or most of you are uh familiar with.
3600:03:09,020 --> 00:03:09,429So,
3700:03:09,440 --> 00:03:22,179Doctor D uh I'd like to start the podcast by having our guests um introduce themselves and elaborate on how you are a pharmacogenomics expert.
3800:03:23,619 --> 00:03:23,800Yeah,
3900:03:23,809 --> 00:03:24,250thank you,
4000:03:24,259 --> 00:03:25,759Becky for having me.
4100:03:25,770 --> 00:03:26,850Uh uh Yes.
4200:03:26,860 --> 00:03:27,289So I am a,
4300:03:27,300 --> 00:03:30,820I am a pharmacist uh with uh a family who is a,
4400:03:30,830 --> 00:03:33,039a doctorate in pharmacokinetics.
4500:03:33,539 --> 00:03:44,520Uh I completed my studies in France and I came as a postdoc uh fellow uh to work in the United States about 20 years ago to work on the pharmacogenomic of anti cancer agents,
4600:03:44,929 --> 00:03:49,160uh primarily uh six Maturin as well as methotrexate.
4700:03:49,169 --> 00:03:50,550After my post doc,
4800:03:50,770 --> 00:03:52,960uh I moved uh in industry for promet.
4900:03:53,490 --> 00:04:01,429So I have a large experience in uh uh the implementation of pharmacogenetics testing in immune mediated inflammatory disease.
5000:04:01,509 --> 00:04:12,550Our lab Rome was the first uh clinical laboratory in the United States to offer the fin uh metyl transfer genotyping as well as the thin metabolites.
5100:04:12,559 --> 00:04:13,029So,
5200:04:13,050 --> 00:04:21,989uh uh of uh of 70 publications in the field and uh I'm very uh very excited to have uh to be on the postcard with you uh uh today.
5300:04:23,660 --> 00:04:24,220All right.
5400:04:24,230 --> 00:04:27,359So thank you for qualifying yourself as an expert.
5500:04:27,369 --> 00:04:27,619So,
5600:04:27,630 --> 00:04:32,839let's jump right in and delve into your current PGX work.
5700:04:32,850 --> 00:04:33,279So,
5800:04:33,489 --> 00:04:36,540if you'll tell us um a little about Prometheus,
5900:04:36,549 --> 00:04:38,000specifically,
6000:04:38,010 --> 00:04:40,350what is Prometheus's mission?
6100:04:40,359 --> 00:04:43,799And how are you guys going about accomplishing your mission?
6200:04:44,760 --> 00:04:44,980Yeah,
6300:04:44,989 --> 00:04:45,700sure.
6400:04:45,709 --> 00:04:47,459Uh So Promet is a,
6500:04:47,470 --> 00:04:52,790is a reference uh clinical laboratory based in Southern California in San Diego.
6600:04:53,230 --> 00:04:56,809Uh The company has been there for uh over 25 years.
6700:04:56,820 --> 00:05:03,950We are uh specialize in the differential diagnosis of autoimmune G I disease uh disorders,
6800:05:04,059 --> 00:05:06,019uh gastrointestinal disorder,
6900:05:06,230 --> 00:05:08,619uh and inflammatory bowel disease.
7000:05:08,980 --> 00:05:10,299And over the years,
7100:05:10,309 --> 00:05:16,600we have developed a portfolio of a differentiated solution to facilitate the diagnosis,
7200:05:16,609 --> 00:05:17,470the prognosis,
7300:05:17,480 --> 00:05:18,429the monitoring,
7400:05:18,660 --> 00:05:21,910as well as therapy selection with pharmacogenetics testing,
7500:05:21,920 --> 00:05:24,730which we are offering to our clinical laboratory.
7600:05:24,829 --> 00:05:26,350And most importantly,
7700:05:26,410 --> 00:05:27,299uh recently,
7800:05:27,309 --> 00:05:35,660we are uh uh developing some uh uh testing solution with the credit topic care test to optimize treatment to uh biologics.
7900:05:36,470 --> 00:05:37,130Ok.
8000:05:37,140 --> 00:05:37,329Well,
8100:05:37,339 --> 00:05:37,450that,
8200:05:37,459 --> 00:05:38,049that's great.
8300:05:38,059 --> 00:05:46,100Can you also tell us uh about the Prois Library of Precision Medicine Tests for inflammatory bowel disease for patients?
8400:05:46,109 --> 00:05:49,230how they benefit medication therapy management.
8500:05:49,239 --> 00:05:56,429Stakeholders across the IB DS patients journey from diagnosis to treatment to disease,
8600:05:56,440 --> 00:06:02,049monitoring through remission and how they differ from other lab tests for IBD and his treatments.
8700:06:02,709 --> 00:06:03,209Yes.
8800:06:03,220 --> 00:06:03,369So,
8900:06:03,380 --> 00:06:04,399so we uh our,
9000:06:04,410 --> 00:06:10,100our clinical laboratory offers some uh highly specialized test to facilitate the,
9100:06:10,109 --> 00:06:16,779the diagnostic of uh to facilitate the differential diagnosis of uh uh inflammatory bowel disease.
9200:06:16,790 --> 00:06:22,359So we are following uh testing solution with uh serological testing,
9300:06:22,529 --> 00:06:23,799for example,
9400:06:23,809 --> 00:06:38,410uh uh piana as as as well as uh macro microbial uh uh antibodies that are present uh uh in Crohn's disease as well as uh over uh auto uh auto antibodies that are present in er colitis.
9500:06:39,339 --> 00:06:43,684These are conditions that are uh uh somewhat difficult to treat.
9600:06:43,704 --> 00:06:49,994Uh And uh we are uh uh offering those tests to uh help uh gastroenterologist.
9700:06:50,015 --> 00:06:51,114Uh uh first of all,
9800:06:51,125 --> 00:07:03,434to establish a differential diagnosis of IBD as compared to other uh condition typically uh uh irritable bowel syndrome as well as over gastrointestinal disorder.
9900:07:03,445 --> 00:07:05,635When the diagnostic is established,
10000:07:05,910 --> 00:07:31,839uh we offer uh testing to uh establish a prognosis where we're gonna in inform the clinician that the patient has a more aggressive uh disease that will require more aggressive treatment where uh we can uh provide the testing solution to initiate uh uh the most appropriate therapy for uh for the patient uh with uh a testing where we are uh basically uh you know,
10100:07:31,850 --> 00:07:36,559establish de determining some genotyping with the fit transferal genotyping.
10200:07:36,570 --> 00:07:37,279For example,
10300:07:37,290 --> 00:07:40,250where we can uh indicate that the patient is,
10400:07:40,260 --> 00:07:45,079is likely uh to present with a side effect to those medication.
10500:07:45,399 --> 00:07:46,170And once you know,
10600:07:46,179 --> 00:07:47,799the the treatment is initiative,
10700:07:47,809 --> 00:08:16,089we have a portfolio of solution uh to facilitate the monitoring of the disease of the inflammatory bowel disease as well as the dosing optimization with uh uh the answer test which uh measure blood level uh for uh uh monoclonal antibodies that are indicated in the treatment of IB start with starting with Infliximab Adalimumab as well as uh Tein and vidal.
10800:08:16,980 --> 00:08:24,040So we have a comprehensive portfolio to uh to surround the clinician with uh a variety of testing solution.
10900:08:24,049 --> 00:08:30,250With our goal being to improve the uh the outcome uh of patients with uh with diabetes.
11000:08:30,260 --> 00:08:34,520And I think that the pharmacist has a very important role to play from that perspective.
11100:08:35,179 --> 00:08:36,039So theory,
11200:08:36,049 --> 00:08:40,239could you elaborate for us more on the predictor test?
11300:08:40,249 --> 00:08:42,758Um especially since you designed that test,
11400:08:42,768 --> 00:08:44,218we'd really like to know,
11500:08:44,489 --> 00:08:45,039um you know,
11600:08:45,049 --> 00:08:49,638what did that take and what role does it play in your suite of testing?
11700:08:51,049 --> 00:08:51,270Yeah.
11800:08:51,280 --> 00:08:51,890Sure.
11900:08:51,900 --> 00:08:52,510So the,
12000:08:52,520 --> 00:08:52,570the,
12100:08:52,580 --> 00:08:52,989the,
12200:08:53,000 --> 00:08:53,229the,
12300:08:53,239 --> 00:08:59,960the predictor test is uh uh is uh is utilized when the patient is receiving treatment.
12400:09:00,280 --> 00:09:18,190It's been speci specifically designed to optimize uh biological uh uh disease modifiers such as Infliximab adalimumab that are co therapies in the treatment of inflammatory bowel disease as well as other immune uh mediated inflammatory.
12500:09:18,200 --> 00:09:21,549This is what the test does is to you connect the blood specimen,
12600:09:22,229 --> 00:09:23,049uh you know,
12700:09:23,059 --> 00:09:24,750with dosing information.
12800:09:25,039 --> 00:09:41,989And what we do is to uh uh provide guidance uh to clinician with uh respect of the best dose to give in order to achieve the best the level which is the most consistent with uh uh the disease control that needs to be achieved for the patient.
12900:09:42,169 --> 00:09:43,729Typically a vast majority,
13000:09:43,739 --> 00:09:46,159about two third of a third to two third,
13100:09:46,169 --> 00:09:54,669a third of patient uh tend to be uh uh unresponsive uh to this uh very expensive medication.
13200:09:54,989 --> 00:09:57,960Uh Not because they don't have the uh you know,
13300:09:57,969 --> 00:09:59,289typically because they have a,
13400:09:59,299 --> 00:09:59,590you know,
13500:09:59,599 --> 00:10:05,599pharmacokinetic uh suboptimal pharmacokinetic uh that makes them uh you know,
13600:10:05,609 --> 00:10:09,440unresponsive because uh not enough drug has been given.
13700:10:09,450 --> 00:10:18,469So what we do with a predictor test is to basically estimate the pa the pharmacokinetic uh parameter for the patient.
13800:10:18,750 --> 00:10:24,729And from then uh re report the best dose uh to give in order to achieve the,
13900:10:24,760 --> 00:10:31,570the level which is consistent with the uh the most uh uh effective disease control to be achieved for the patient.
14000:10:32,169 --> 00:10:33,059So we are offering,
14100:10:33,070 --> 00:10:38,049we have developed a test for the Infliximab as well as Adalimumab which is Humira,
14200:10:38,909 --> 00:10:41,309but these are antimony causes factor.
14300:10:41,460 --> 00:10:49,549And we are also developing the test for vidur as well as uh is that are widely used also in the treatment of,
14400:10:49,559 --> 00:10:51,969of uh inflammatory bubble disease.
14500:10:51,979 --> 00:10:52,669Wow,
14600:10:52,679 --> 00:10:55,450uh for MET is a suite of tests.
14700:10:55,460 --> 00:11:00,940Goes well beyond um the PGX testing that our audience is most familiar with,
14800:11:01,299 --> 00:11:08,679uh which typically only includes snips for cyp genes and some pharmacodynamic genes.
14900:11:08,690 --> 00:11:31,424This is really exciting um genes and biomarkers related to immunology are not commonly found in what I call the box PGX tests such as those uh made by large uh laboratory manufacturing companies um where the panel has a set number of genes and uh you know,
15000:11:31,434 --> 00:11:36,054it was developed by a larger laboratory for maybe smaller laboratories use.
15100:11:36,729 --> 00:11:39,010So my understanding,
15200:11:39,020 --> 00:11:53,729having talked with you extensively theory is that immunology has fewer PGX test available because it's actually more difficult say than oncology to research and develop tests.
15300:11:53,739 --> 00:11:54,119So,
15400:11:54,130 --> 00:12:00,729could you elaborate for our audience on the difficulties that are associated with immunology,
15500:12:00,739 --> 00:12:05,830research and developing tests uh for immunology versus say oncology?
15600:12:06,330 --> 00:12:06,530Yeah,
15700:12:06,539 --> 00:12:07,049sure.
15800:12:07,059 --> 00:12:09,969So in uh in immunology,
15900:12:09,979 --> 00:12:11,590as compared to oncology,
16000:12:11,599 --> 00:12:17,169there is no such a thing such as a somatic mutation where for example,
16100:12:17,179 --> 00:12:18,429you're gonna have a behalf,
16200:12:18,440 --> 00:12:18,659you know,
16300:12:18,669 --> 00:12:20,349that indicates that the patient,
16400:12:20,679 --> 00:12:20,919you know,
16500:12:20,929 --> 00:12:25,239is likely to benefit or not from some treatment in immunology.
16600:12:25,250 --> 00:12:26,750This is far more complicated,
16700:12:26,760 --> 00:12:28,830complicated for the reason,
16800:12:29,239 --> 00:12:31,020starting with uh the fact that,
16900:12:31,030 --> 00:12:31,179you know,
17000:12:31,190 --> 00:12:36,219the response to this uh medication uh are multifactorial.
17100:12:36,260 --> 00:12:37,820And the fact that uh you know,
17200:12:37,830 --> 00:12:39,380the mutation that uh the,
17300:12:39,390 --> 00:12:39,619the,
17400:12:39,630 --> 00:12:45,190the single nucleotide polymorphism in the GM line which uh uh you know,
17500:12:45,200 --> 00:12:52,429can potentially associate with uh with outcome uh uh uh uh a lo in advance,
17600:12:52,440 --> 00:12:58,359meaning that uh they're gonna have a weak association uh with a response to those medications.
17700:12:58,369 --> 00:13:09,609So there is a necessity in immunology to combine multiple genetic polymorphism together in order to achieve uh some uh performances characteristics that will make uh you know,
17800:13:09,619 --> 00:13:09,859the,
17900:13:09,869 --> 00:13:10,380the,
18000:13:10,390 --> 00:13:10,520the,
18100:13:10,530 --> 00:13:13,219the clinician uh you know,
18200:13:13,419 --> 00:13:15,619uh order the test and most importantly,
18300:13:15,630 --> 00:13:15,840the,
18400:13:15,849 --> 00:13:16,179the,
18500:13:16,190 --> 00:13:17,739the payer to pay for the test.
18600:13:17,750 --> 00:13:20,469So this field has been uh you know,
18700:13:20,479 --> 00:13:20,679is,
18800:13:20,690 --> 00:13:21,705is moving for,
18900:13:21,715 --> 00:13:21,994you know,
19000:13:22,005 --> 00:13:24,575there are some tests that are being developed right now.
19100:13:24,924 --> 00:13:39,034But the biggest challenge is to be able to achieve again the the threshold of uh of performance that makes the test is variable enough uh to be uh again ordered by the clinician and the utilize uh to the benefit of the patient.
19200:13:39,659 --> 00:13:41,200I couldn't agree with you more.
19300:13:41,210 --> 00:13:53,489Um I've worked on the payer side or market access side of pharmacogenomics and even uh with a box test for which there's um a lot of research data available,
19400:13:53,500 --> 00:13:55,119even with those,
19500:13:55,130 --> 00:13:59,760it's sometimes difficult uh to get payers um to see the value.
19600:13:59,770 --> 00:14:01,640So I absolutely agree with you.
19700:14:01,940 --> 00:14:03,679Um The fact that you guys are,
19800:14:03,690 --> 00:14:11,789are uh investing in producing the data necessary says a lot about your laboratory.
19900:14:11,979 --> 00:14:12,559Um you know,
20000:14:12,570 --> 00:14:15,380and how committed you are to this testing and,
20100:14:15,390 --> 00:14:17,320and how you believe in the testing.
20200:14:18,039 --> 00:14:23,640So I just want to make sure that our audience recognizes that,
20300:14:24,359 --> 00:14:24,619you know,
20400:14:24,630 --> 00:14:31,820Prometheus doesn't simply provide tests to determine if drugs for IBD will be effective and safe.
20500:14:32,190 --> 00:14:36,900Um And maybe what the dose of the drug should be for the patient,
20600:14:36,909 --> 00:14:40,219but you have that whole suite of tests.
20700:14:40,229 --> 00:14:47,380Um the diagnostic test for the differential diagnosis all the way through remission.
20800:14:48,030 --> 00:14:53,390So can you elaborate you elaborated on it some in the previous question?
20900:14:53,400 --> 00:15:01,229But um can you tell us the difference between how you had to actually develop the test?
21000:15:01,520 --> 00:15:02,530Um You didn't,
21100:15:02,539 --> 00:15:03,059in other words,
21200:15:03,070 --> 00:15:10,659purchase a test from another manufacturer with the biomarkers that you include in your testing.
21300:15:10,669 --> 00:15:16,830Can you elaborate on how much more difficult it is to to develop a test from scratch?
21400:15:18,169 --> 00:15:18,320Yeah,
21500:15:18,330 --> 00:15:18,659sure.
21600:15:18,669 --> 00:15:18,809I mean,
21700:15:18,820 --> 00:15:22,070this is this is challenging for multiple and first of all,
21800:15:22,080 --> 00:15:23,130you need to have the,
21900:15:23,419 --> 00:15:27,450you need to have a clinical data set available with specimen available.
22000:15:27,460 --> 00:15:28,159Uh you know,
22100:15:28,169 --> 00:15:28,780in front,
22200:15:28,859 --> 00:15:29,770obviously,
22300:15:29,859 --> 00:15:30,890available.
22400:15:31,200 --> 00:15:35,890Uh So we are leveraging a pro meters a large bi bank of specimen.
22500:15:36,299 --> 00:15:37,190Uh as I said,
22600:15:37,200 --> 00:15:39,719Prometheus has been founded 25 years ago.
22700:15:39,729 --> 00:15:40,599So over the,
22800:15:40,760 --> 00:15:41,919the past two decades,
22900:15:41,929 --> 00:15:54,849we have been able to assemble a large uh substrate of data and specimen which we are uh uh using to uh uh establish our proof of concept if you will.
23000:15:54,859 --> 00:16:07,559And then when we have uh identify some genetic polymorphism that are uh adequately uh associated with uh uh disease outcome and disease progression as well as uh toxicity.
23100:16:07,969 --> 00:16:11,469Then we are entering validation phase where we are uh you know,
23200:16:11,570 --> 00:16:14,789using validation cohorts where we are again,
23300:16:14,969 --> 00:16:22,630combining multiple modalities together uh patient demographic as well as genetic marker together with theological marker.
23400:16:22,640 --> 00:16:23,190Actually,
23500:16:23,500 --> 00:16:27,419to come up with some Multivariate models that are uh again,
23600:16:27,429 --> 00:16:39,250bringing the performances characteristics of the pharmacogenomic test or its combination with our marker to the level where it's supposed to be in the first place to meet uh uh payer.
23700:16:39,650 --> 00:16:41,190And uh obviously,
23800:16:41,200 --> 00:16:41,760again,
23900:16:41,770 --> 00:16:45,320the patient uh to the benefit of the patient and to,
24000:16:45,330 --> 00:16:46,619to improve its outcome,
24100:16:46,739 --> 00:16:47,429the outcome.
24200:16:48,340 --> 00:16:53,380I think what you're describing really is the future of pharmacogenomics.
24300:16:53,390 --> 00:16:54,599Um In other words,
24400:16:54,609 --> 00:17:03,419not singing out pharmacogenomics as you know the end all and be all in the treatment paradigm.
24500:17:03,559 --> 00:17:08,040But using a PGX test in combination with,
24600:17:08,050 --> 00:17:09,069like you mentioned,
24700:17:09,250 --> 00:17:11,160other serological tests,
24800:17:11,170 --> 00:17:12,959maybe other genetic tests.
24900:17:13,290 --> 00:17:14,890Um But you know,
25000:17:14,900 --> 00:17:25,869I think what we want our audience to really wrap their heads around is that PGX is just a piece of that larger puzzle um from diagnosis to treatment to,
25100:17:25,880 --> 00:17:26,910to remission.
25200:17:27,239 --> 00:17:29,880So I think you guys are absolutely,
25300:17:29,890 --> 00:17:31,579you're already in the future.
25400:17:31,589 --> 00:17:32,849In other words,
25500:17:32,859 --> 00:17:33,130you know,
25600:17:33,140 --> 00:17:39,689you're already providing all these different uh tests um like you mentioned to,
25700:17:39,699 --> 00:17:44,310to facilitate from diagnosis to remission to remission.
25800:17:44,660 --> 00:17:45,520That's correct.
25900:17:45,530 --> 00:17:45,829Yeah.
26000:17:46,349 --> 00:17:55,089So um you've given us so much great information about uh the tests that that you guys offer.
26100:17:55,329 --> 00:18:02,060Can you explain to our audience um your newest test?
26200:18:02,069 --> 00:18:03,859Uh the responder test.
26300:18:04,150 --> 00:18:12,979And um what role it will play in the paradigm from the diagnosis of IBD to remission?
26400:18:14,050 --> 00:18:14,260Yeah,
26500:18:14,270 --> 00:18:14,760sure.
26600:18:14,770 --> 00:18:15,569So we,
26700:18:15,579 --> 00:18:18,069we are doing things a little bit different than other.
26800:18:18,079 --> 00:18:19,489We do believe that uh you know,
26900:18:19,500 --> 00:18:21,449the it has to be simple.
27000:18:21,459 --> 00:18:24,189Uh uh We can obviously construct some very,
27100:18:24,199 --> 00:18:33,530very complex algorithm and there are some tests that do that with a very sophisticated machine learning based tools that are available using neural networks,
27200:18:33,540 --> 00:18:33,729you know,
27300:18:33,739 --> 00:18:34,790those sorts of things.
27400:18:34,800 --> 00:18:39,729But we have taken on a different approach where with the responder test,
27500:18:39,739 --> 00:18:40,329we are basically,
27600:18:40,339 --> 00:18:45,160we are taking an approach which is very simple to address the first and foremost.
27700:18:45,170 --> 00:18:53,020Most important aspect of responding uh predicting response to uh to medication is the pharmacokinetics.
27800:18:53,280 --> 00:19:03,250Uh You cannot be responding to a drug if the drug is not given and you obviously cannot respond to a drug if the drug is not metabolized adequately.
27900:19:03,359 --> 00:19:06,349And this is what we are doing with the responder test.
28000:19:06,579 --> 00:19:09,010We are addressing some uh uh you know,
28100:19:09,020 --> 00:19:11,630fundamental issues with those uh biologist,
28200:19:11,640 --> 00:19:12,410for example,
28300:19:12,660 --> 00:19:15,170uh the anti tumor necrosis factors.
28400:19:15,180 --> 00:19:15,650So,
28500:19:15,750 --> 00:19:19,199such as uh Infliximab and Adalimumab,
28600:19:19,209 --> 00:19:23,050it is well known uh that uh uh those drugs,
28700:19:23,060 --> 00:19:25,689first of all are prone to immunization.
28800:19:25,989 --> 00:19:36,949Uh Meaning that uh uh the drug itself uh is recognized by the immune system uh and digested by the antigen presenting cells.
28900:19:36,959 --> 00:19:42,209If you will uh where you gonna have uh uh an immune uh uh response,
29000:19:42,380 --> 00:19:56,979uh mounted a cancer drug to produce uh immunogen that will severely impact its pharmacokinetics where the labels will be inadequate to produce uh the desired uh anti-inflammatory effects.
29100:19:56,989 --> 00:19:57,150So,
29200:19:57,160 --> 00:19:58,890we are with the risk conductors,
29300:19:58,900 --> 00:20:01,040we are combining two things together.
29400:20:01,189 --> 00:20:07,959First of all is the genetic test itself which uh predicts the risk of immun immunization.
29500:20:07,969 --> 00:20:18,010The name of the test is on HL A uh DQ A 105 ali uh that uh uh promotes the presentation of the,
29600:20:18,020 --> 00:20:19,130of the,
29700:20:19,140 --> 00:20:19,910of Infliximab,
29800:20:20,010 --> 00:20:20,750for example,
29900:20:20,760 --> 00:20:32,130to the T cell repertoire in order to uh promote the Ronon expansion and the formation of the anti antibodies together with uh another dimension which is the clearance,
30000:20:32,140 --> 00:20:33,670which is as important.
30100:20:33,949 --> 00:20:36,209Uh One of the key issue is the,
30200:20:36,219 --> 00:20:36,770the,
30300:20:36,780 --> 00:20:41,239the monoclonal antibodies and uh such as Infliximab or Adalimumab.
30400:20:41,329 --> 00:20:42,280But in fact,
30500:20:42,290 --> 00:20:45,890a neon antibodies that those drugs are uh you know,
30600:20:45,900 --> 00:20:49,010cleared and consumed uh from the,
30700:20:49,020 --> 00:20:50,949from the central compartment if you will,
30800:20:50,959 --> 00:20:54,520since we are doing a little bit of uh uh pharmacokinetics here.
30900:20:54,530 --> 00:20:56,020And uh uh you know,
31000:20:56,030 --> 00:21:06,670if the patient present who is uh a high degree of inflammatory burden is gonna have uh the patient will have a high clearance and that's gonna worsen uh in the,
31100:21:06,680 --> 00:21:13,939in the presence again of the HL AD Q A 105 genetic marker that uh associate with uh immunization.
31200:21:13,949 --> 00:21:16,859So I but this is a combination of both,
31300:21:17,199 --> 00:21:19,359these are the predictive factors of pharmacokinetic,
31400:21:20,359 --> 00:21:38,209which we combine together where the patient presenting with a risk of immunization as well as accelerated clearance due to the fact that the patient has high inflammation or due to the fact that they are so intrinsic pharmacokinetic properties that makes that the patient,
31500:21:38,219 --> 00:21:38,300you know,
31600:21:38,310 --> 00:21:39,479will clear the drug very,
31700:21:39,489 --> 00:21:40,260very fast.
31800:21:40,560 --> 00:21:41,670For example,
31900:21:41,680 --> 00:21:46,819due to the inefficient uh recirculation of the drug itself with the new,
32000:21:46,869 --> 00:21:46,930the,
32100:21:46,939 --> 00:21:50,599the the in the reticular on the system.
32200:21:50,920 --> 00:21:51,619Together,
32300:21:51,630 --> 00:22:02,109those patients presenting with uh uh together these uh poor prognostic factor of pharmacokinetic origin will tend to be severely underdose,
32400:22:02,380 --> 00:22:06,719will not be responding to the drug uh adequately as and they,
32500:22:06,729 --> 00:22:10,719and they probably should in the first place if you are able to address uh you know,
32600:22:10,729 --> 00:22:12,270the the the exposure.
32700:22:12,439 --> 00:22:14,079So what we do with this test,
32800:22:14,089 --> 00:22:21,640we will be able to inform uh the clinic that the patient is at risk of achieving,
32900:22:21,650 --> 00:22:30,829of achieving suboptimal pharmacokinetics and therefore being able to adjust the dose uh uh to start with more adequately.
33000:22:30,839 --> 00:22:38,650So that the the the proper uh exposure is achieved uh during induction to again to,
33100:22:38,660 --> 00:22:39,040to,
33200:22:39,050 --> 00:22:39,380to,
33300:22:39,390 --> 00:22:40,890to achieve a better outcome.
33400:22:41,040 --> 00:22:47,270And I think the pharmacist will have a very important role to play here in terms of absolutely,
33500:22:47,280 --> 00:22:51,239that information is priceless in the management of these medications.
33600:22:51,250 --> 00:22:54,930So thanks for elaborating on that.
33700:22:56,010 --> 00:22:59,040And if I may add in our previous conversation,
33800:22:59,050 --> 00:23:00,810uh before the recording of podcast,
33900:23:00,819 --> 00:23:08,869we had discussed um you guys' robust platform for collaborating with payers to obtain market access and reimbursements for the test.
34000:23:09,109 --> 00:23:14,109But without stealing the Thunder from uh Prometheus market access and reimbursement team,
34100:23:14,199 --> 00:23:22,619can you please uh briefly detail how Prometheus has proactively worked with payers to solve the problem.
34200:23:22,920 --> 00:23:27,349Um the population health problem by building the evidence payers want,
34300:23:27,359 --> 00:23:41,170want to see um about your test before you go to the market and then build the test and then hope the payers will see the value and the result and then that will improve the market access and reimbursement for your um precision medicine test.
34400:23:42,160 --> 00:23:42,339Yeah.
34500:23:42,349 --> 00:23:43,180So briefly I can,
34600:23:43,189 --> 00:23:43,579I'm,
34700:23:43,589 --> 00:23:46,619I'm probably not the right person to answer that question.
34800:23:46,630 --> 00:23:47,369We have a very,
34900:23:47,380 --> 00:23:52,400very efficient market access group uh uh pro meters that does a splendid job.
35000:23:52,410 --> 00:23:59,780But uh uh uh what I can tell you that we have an evidence uh uh development plan in place where we,
35100:23:59,790 --> 00:24:14,000we are establishing the clinical utility of our testing solution by demonstrating uh the payer value uh with respect of uh patient management and uh uh and the,
35200:24:14,010 --> 00:24:16,630and the impact of our technology on the,
35300:24:16,640 --> 00:24:18,119on physician behavior.
35400:24:18,430 --> 00:24:21,319Uh We have uh uh already uh you know,
35500:24:21,329 --> 00:24:25,160commercialized uh two of those tests for which we have initiated,
35600:24:25,170 --> 00:24:29,040initiated the Power studies uh that uh uh you know,
35700:24:29,050 --> 00:24:32,000already provide uh you know,
35800:24:32,104 --> 00:24:34,484differentiated and the value to,
35900:24:34,494 --> 00:24:35,915to the payer where we are,
36000:24:35,925 --> 00:24:36,025the,
36100:24:36,035 --> 00:24:46,005the clinicians are basically using our technology to make treatment decision uh as well as uh some prospective clinicality study which we are initiating,
36200:24:46,145 --> 00:24:47,555initiating to.
36300:24:47,564 --> 00:24:48,574Um uh again,
36400:24:48,584 --> 00:24:49,425demonstrate the,
36500:24:49,435 --> 00:24:49,915the,
36600:24:49,925 --> 00:24:50,244the,
36700:24:50,255 --> 00:24:53,594the payer value you uh uh we can certainly follow up with,
36800:24:53,604 --> 00:24:58,755uh you can certainly follow up with our market access group uh uh as appropriate there.
36900:24:58,765 --> 00:25:00,765Uh They can fill you with more information.
37000:25:01,349 --> 00:25:01,589No,
37100:25:01,599 --> 00:25:02,520that totally makes sense.
37200:25:02,530 --> 00:25:03,310That totally makes sense.
37300:25:03,319 --> 00:25:10,890But um we're excited that you're also farm d So how did you get to this role of outside the box path?
37400:25:10,900 --> 00:25:11,550There?
37500:25:11,640 --> 00:25:17,530There may be a pharmacist student or pharmacist wanting to switch or transition into a role such as yours,
37600:25:17,540 --> 00:25:19,609which is a Chief Scientific Officer.
37700:25:19,619 --> 00:25:20,609I want to learn more.
37800:25:20,619 --> 00:25:23,920So how would you um can you talk a little bit about that?
37900:25:24,560 --> 00:25:24,780Well,
38000:25:24,790 --> 00:25:26,270we are clinical laboratories.
38100:25:26,280 --> 00:25:29,400So in order to uh uh to be in my role,
38200:25:29,410 --> 00:25:34,020you need to have uh uh you need to have expertise in clinical laboratory science.
38300:25:34,030 --> 00:25:36,140So for the students is basically,
38400:25:36,150 --> 00:25:36,300you know,
38500:25:36,310 --> 00:25:40,770to do the family degree and then complete the family degree with uh a doctorate,
38600:25:40,780 --> 00:25:40,930you know,
38700:25:40,939 --> 00:25:44,260which is uh focus on clinical laboratory science.
38800:25:44,270 --> 00:25:46,079So you can achieve uh uh you know,
38900:25:46,089 --> 00:25:47,640the all the elements you need to be,
39000:25:47,650 --> 00:25:48,219for example,
39100:25:48,229 --> 00:25:53,189board certified uh as uh as as medical laboratory director.
39200:25:53,199 --> 00:25:55,160So you can uh uh so,
39300:25:55,170 --> 00:25:55,589uh yeah,
39400:25:55,599 --> 00:25:56,030this is,
39500:25:56,040 --> 00:25:56,400this is,
39600:25:56,410 --> 00:25:57,209this is uh you know,
39700:25:57,219 --> 00:25:59,160a great opportunity I think for pharmacies,
39800:25:59,170 --> 00:26:10,800there is an absolute need to uh have the clinical pharmacist provide uh uh drug information to healthcare professional as well as uh assist patient with the monitoring of their disease,
39900:26:10,810 --> 00:26:15,229the effectiveness of the therapy and um and uh you know,
40000:26:15,239 --> 00:26:16,060monitoring the,
40100:26:16,069 --> 00:26:20,969the side effect and the toxicity from uh from those uh those medication.
40200:26:24,650 --> 00:26:24,959Well,
40300:26:24,969 --> 00:26:32,119the I know our audience is going to have uh additional questions for you.
40400:26:32,130 --> 00:26:32,540I mean,
40500:26:32,989 --> 00:26:35,609you've provided them with so much great information,
40600:26:35,619 --> 00:26:44,959but it's only the beginning of what they could possibly learn um about um the testing that you do for IBD and,
40700:26:44,969 --> 00:26:46,729and even your career path.
40800:26:47,050 --> 00:26:47,530So,
40900:26:47,540 --> 00:26:49,300if you wouldn't mind telling us,
41000:26:49,310 --> 00:26:51,359um because we have to wrap up,
41100:26:51,369 --> 00:26:52,670unfortunately,
41200:26:53,150 --> 00:26:55,810this episode of the podcast,
41300:26:55,819 --> 00:27:00,250uh could you tell us how our audience members might be able to contact you directly.
41400:27:01,260 --> 00:27:01,449Yeah,
41500:27:01,459 --> 00:27:07,079I can be contacted on my uh on my email at TT W at como slab dot com.
41600:27:07,949 --> 00:27:08,810All right.
41700:27:09,069 --> 00:27:09,300Well,
41800:27:09,310 --> 00:27:14,290thank you again so much uh for joining us on this episode.
41900:27:14,300 --> 00:27:15,290We really,
42000:27:15,300 --> 00:27:29,530really hope that our listeners um ideas of not only what PGX can be but how PGX can be utilized in a comprehensive testing suite.
42100:27:29,709 --> 00:27:35,670We really hope that our a our audience will um listen in and learn this information.
42200:27:36,280 --> 00:27:37,869Um And to our audience,
42300:27:37,880 --> 00:27:39,439thank you for tuning in.
42400:27:39,449 --> 00:27:42,619We really hope that you've learned from this episode.
42500:27:43,130 --> 00:27:46,339Uh We do a whole lot of PG Xing here on this podcast.
42600:27:46,349 --> 00:27:48,380We talk about PGX Science,
42700:27:48,390 --> 00:27:52,030clinical application and the business of PGX.
42800:27:52,260 --> 00:27:54,880So we'd love to hear about from you.
42900:27:55,099 --> 00:27:56,479I love to hear from you.
43000:27:56,489 --> 00:27:58,439Um What can we teach you?
43100:27:58,449 --> 00:28:00,920What more can we teach you through our podcast?
43200:28:00,930 --> 00:28:12,349So please drop us a message on linkedin and let us know and please share this link to this podcast link episode with everyone so they can tune in and listen to the PGX for promises podcast.
43300:28:12,520 --> 00:28:15,369Leave us a review on Apple podcast or Spotify.
43400:28:15,459 --> 00:28:18,130And you can also visit us on PGX four,
43500:28:18,140 --> 00:28:22,989the number four Rx dot com to listen to all our other episodes.
43600:28:23,000 --> 00:28:23,079Well,
43700:28:23,089 --> 00:28:23,790thank you.
43800:28:24,199 --> 00:28:28,750Thanks for your interest in PGX and for spending some time with us.
43900:28:28,760 --> 00:28:35,670Please share this podcast and leave us a review on Apple podcasts or Spotify for all of our episodes.
44000:28:35,680 --> 00:28:39,390Please visit PGX four Rx dot com.
44100:28:39,569 --> 00:28:43,380That's PGX four Rx dot com.
 

The Extra Dose: User Conference Post-Show Part One | Framework Focus

This is part one of the three-part FrameworkLTC User Conference Post-Show series. This series is hosted by the Pharmacy Podcast Network’s own Todd Eury. In this series, Todd chats with SoftWriters’ team members, exhibitors, partners, and conference attendees live from the show floor. This episode features Mark Fulton, Cara Whipple, Dan Kennedy, Karen Sims, and Derek Taylor. 

Let’s Review the Timeline | Road2Match Day

In this episode, we will talk about the various things you should be working on and when, as you prepare for your residency application submission. Send me an email at info@reziprep.com to receive a free timeline with all of the details discussed in today's episode. 

A Surprising Way for Pharmacists to Improve Patient Outcomes | Pivoting Pharmacy with Nutrigenomics

As a pharmacist, I’m sure you're all too familiar with the constant revolving door cycle our healthcare system puts our patients in. But how can we help break the endless cycle plaguing our patients and truly make a change so they can start feeling better for good?
Links mentioned in show: https://www.raisethescript.com/masterclass

It’s a Mad Honey World | Neural Pharm Podcast

And we just live in it. All about the hallucinogenic honey from the mountains of Turkey and Nepal.
 
Foot notes:
UK article on Psilocybin therapy cost effectiveness:
McCrone P, et al. Cost effectiveness of psilocybin assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychological Medicine. 2 June 2023. https://www.cambridge.org/core/journals/psychological-medicine/article/costeffectiveness-of-psilocybinassisted-therapy-for-severe-depression-exploratory-findings-from-a-decision-analytic-model/8594CAC2F8D60F8C7B9A1CE3C3195B74
MDMA Assisted Therapy for Social Anxiety Disorder—Phase II trial being conducted at Portland (OR) Psychotherapy, link here for those interested in finding out more information or enrolling: https://portlandmdmatherapy.com/participate/
Krane, K. HHS Call to reschedule marijuana is a big deal: here’s why. Forbes. 31 Aug 2023. https://www.forbes.com/sites/kriskrane/2023/08/31/hhs-call-to-reschedule-marijuana-is-a-big-deal-heres-why/?sh=af122092a4a7
 
 
Beasley M, et al. Poisoning due to tutin in honey—a report of an outbreak in New Zealand. The New Zealand Medical Journal. 2018; 131(1473): 59-71. https://pubmed.ncbi.nlm.nih.gov/29649198/
Bryce E. The Strange History of Mad Honey. Modern Farmer. 2014. https://modernfarmer.com/2014/09/strange-history-hallucinogenic-mad-honey/
Honey. Natural Medicines comprehensive database. Last updated 12 June 2023. Accessed 15 Oct 2023.
How eating “Mad Honey” cost Pompey the Great 1000 soldiers. Texas A&M Research. 3 Nov 2014. https://research.tamu.edu/2014/11/03/how-eating-mad-honey-cost-pompey-the-great-1000-soldiers/
Jansen S, et al. Grayanotoxin poisoning: mad honey disease and beyond. Cardiovascular Toxicology. 2012; 12(3): 208-215. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404272/
Johnson S. “Mad Honey: the rare hallucinogen from the mountains of Nepal. Big Think. 26 Dec 2022. https://bigthink.com/health/mad-honey/
Ozhan H, et al. Cardiac emergencies caused by honey ingestion: a single centre experience. Emergency Medicine Journal. 2004; 21(6:) 742-744. https://pubmed.ncbi.nlm.nih.gov/15496712/
Ullah S, et al. Mad Honey: uses, intoxicating/poisoning effects, diagnosis, and treatment. RSC Advances. 2018; 8(33): 18635-18646.

The Value of Integrated Care in Specialty Pharmacy | NASP Specialty Pharmacy Podcast

Jennifer Donovan, Pharm D, is the vice president of clinical services at Shields Health Solutions. In thisrole, Jen leads the Clinical Services, Training and Outcomes teams. She’s responsible for ensuring Shieldsprovides best-in-class patient care that’s evidence-based and adheres to external requirements, workingcross functionally with various departments.Prior to Shields, Jen was the Associate Dean for the School of Pharmacy – Worcester/Manchester andProfessor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences in Worcester,MA. Jen earned a Doctor of Pharmacy degree from Massachusetts College of Pharmacy and HealthSciences and completed a pharmacy practice residency at UMass Memorial Medical Center.Jen lives in the New England area with her husband and two kids.